SulAmérica and Rede D’Or São Luiz have announced a combination
SulAmérica (B3:SULA11), a leading insurance company in Brazil, has announced a combination with Rede D’Or São Luiz S.A. (B3:RDOR3), the largest Brazilian hospital network. The companies had a combined market value of approximately US$21 billion on 18 February 2022.
SulAmérica is one of the largest insurance companies in Brazil and operates in the health and dental insurance, life and pension plans, and asset management sectors. The company was founded in 1895 and is headquartered in Rio de Janeiro, Brazil.
Rede D’Or is the largest integrated healthcare network in Brazil, operating in the health sector, with an extensive network of private hospitals.
One of Oaklins’ teams in Brazil acted as the sole financial advisor to SulAmérica on its combination with Rede D’Or São Luiz S.A. The transaction will be submitted for approvals at shareholders’ meetings of both companies and to relevant regulatory agencies. Once the closing date is defined the companies will inform the market.
Porozmawiaj z zespołem obsługi transakcji
Richard Rainer
Oaklins Olimpia Partners
Powiązane transakcje
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Więcej informacjiAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Więcej informacjiXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Więcej informacji